Immunovant, Inc. (NASDAQ:IMVT) CTO Sells $80,912.20 in Stock

Immunovant, Inc. (NASDAQ:IMVT - Get Free Report) CTO Jay S. Stout sold 2,740 shares of the stock in a transaction on Wednesday, October 23rd. The stock was sold at an average price of $29.53, for a total value of $80,912.20. Following the completion of the sale, the chief technology officer now directly owns 142,186 shares in the company, valued at $4,198,752.58. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Immunovant Stock Down 0.9 %

Shares of NASDAQ:IMVT traded down $0.28 on Friday, reaching $30.22. The company had a trading volume of 315,939 shares, compared to its average volume of 1,098,927. Immunovant, Inc. has a twelve month low of $24.67 and a twelve month high of $45.58. The stock has a 50-day moving average price of $30.07 and a 200 day moving average price of $28.95. The stock has a market capitalization of $4.42 billion, a P/E ratio of -15.91 and a beta of 0.66.

Immunovant (NASDAQ:IMVT - Get Free Report) last announced its quarterly earnings results on Tuesday, August 6th. The company reported ($0.60) earnings per share for the quarter, missing analysts' consensus estimates of ($0.53) by ($0.07). During the same period in the prior year, the business earned ($0.57) earnings per share. On average, sell-side analysts predict that Immunovant, Inc. will post -2.43 earnings per share for the current fiscal year.

Institutional Trading of Immunovant

A number of institutional investors and hedge funds have recently made changes to their positions in IMVT. Quest Partners LLC lifted its position in shares of Immunovant by 216.7% in the second quarter. Quest Partners LLC now owns 2,610 shares of the company's stock worth $69,000 after buying an additional 1,786 shares during the last quarter. Headlands Technologies LLC acquired a new position in shares of Immunovant during the 2nd quarter worth about $77,000. EntryPoint Capital LLC lifted its position in shares of Immunovant by 288.8% during the 1st quarter. EntryPoint Capital LLC now owns 2,912 shares of the company's stock worth $94,000 after purchasing an additional 2,163 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Immunovant by 21.4% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,294 shares of the company's stock worth $148,000 after purchasing an additional 934 shares during the last quarter. Finally, Bank Pictet & Cie Europe AG acquired a new position in shares of Immunovant during the 3rd quarter worth about $261,000. Institutional investors and hedge funds own 47.08% of the company's stock.

Analyst Ratings Changes

Several brokerages have weighed in on IMVT. JPMorgan Chase & Co. dropped their target price on Immunovant from $51.00 to $46.00 and set an "overweight" rating on the stock in a research report on Thursday, August 8th. Raymond James reaffirmed an "outperform" rating and set a $36.00 target price on shares of Immunovant in a report on Thursday, October 10th. Cantor Fitzgerald reiterated an "overweight" rating on shares of Immunovant in a research report on Monday, September 9th. Oppenheimer increased their price target on Immunovant from $47.00 to $53.00 and gave the company an "outperform" rating in a research report on Wednesday, October 9th. Finally, UBS Group dropped their target price on Immunovant from $42.00 to $41.00 and set a "buy" rating on the stock in a report on Tuesday, August 13th. Eleven research analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has an average rating of "Buy" and an average target price of $48.10.

Immunovant Company Profile

Immunovant, Inc, a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.